Roche Commits Up To $1bn For Blueprint's Immunokinase Inhibitors
This article was originally published in Scrip
Executive Summary
When Blueprint Medicines Corp. sought a partner to help advance its kinase inhibitors with the potential to boost immune responses to cancer, the company came up with a short list of ideal big pharma collaborators and Roche rose to the top.
You may also be interested in...
Oncology Focused Investment Comes Into Its Own
UBS closed its $471m Oncology Impact Fund, a specialist investment vehicle for early stage oncology, in April this year. But it was by no means the first commercial investment vehicle to focus solely on oncology. Nextech Invest raised its fourth oncology fund in July this year.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.